Loading...
Products:Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Anti-RNA polymerase II CTD repeat YSPTSPS (phospho S2) antibody
See all RNA polymerase II CTD repeat YSPTSPS products (17) ...
Rabbit polyclonal to RNA polymerase II CTD repeat YSPTSPS (phospho S2)
IHC-Pmore details
Reacts with
Mouse, Human
Phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II around serine 2 of the C-terminal repeat YSPTSPS.
Human Ovarian Carcinoma, Mouse Teratoma.
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.09% Sodium Azide
Constituents: 0.1% BSA, Tris buffered saline
Concentration information loading...
Immunogen affinity purified
Polyclonal
IgG
Epigenetics and Nuclear Signaling >> Transcription >> RNA polymerase
Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription >> Polymerase
Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription
Our Abpromise guarantee covers the use of ab84988 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: 1/100 - 1/500.
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Acts as a RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicate and transcriptase for the viral RNA circular genome.
Belongs to the RNA polymerase beta' chain family.
The tandem 7 residues repeats in the C-terminal domain (CTD) can be highly phosphorylated. The phosphorylation activates Pol II. Phosphorylation occurs mainly at residues 'Ser-2' and 'Ser-5' of the heptapeptide repeat and is mediated, at least, by CDK7 and CDK9. CDK7 phosphorylation of POLR2A associated with DNA promotes transcription initiation by triggering dissociation from DNA. Phosphorylation also takes place at 'Ser-7' of the heptapepdtide repeat, which is required for efficient transcription of snRNA genes and processing of the transcripts. The phosphorylation state is believed to result from the balanced action of site-specific CTD kinases and phosphatases, and a "CTD code" that specifies the position of Pol II within the transcription cycle has been proposed.
Dephosphorylated by the protein phosphatase CTDSP1.
Ubiquitinated by WWP2 leading to proteasomal degradation.
Methylated at Arg-1810 by CARM1. Methylation occurs only when the CTD is hypophosphorylated, and phosphorylation at Ser-1805 and Ser-1808 prevent methylation (in vitro). It is assumed that methylation occurs prior to phosphorylation and transcription initiation. CTD methylation may facilitate the expression of select RNAs.
Nucleus.
Target information above from: UniProt accessionP24928
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - RNA polymerase II (phospho S2) antibody (ab84988)

ab84988 at 1/250 dilution staining RNA Polymerase II in serial sections of human ovarian carcinoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue. Detection: DAB staining.
Mock phosphatase treated section (left) or calf intestinal phosphatase-treated section (right).
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - RNA polymerase II (phospho S2) antibody (ab84988)

ab84988 at 1/250 dilution staining RNA Polymerase II in serial sections of mouse teratoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue. Detection: DAB staining. Mock phosphatase treated section (left) or calf intestinal phosphatase-treated section (right).
ab84988 has not yet been referenced specifically in any publications.
Publishing research using ab84988? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:

ab84988 at 1/250 dilution staining RNA Polymerase II in serial sections of human ovarian carcinoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue. Detection: DAB staining.
Mock phosphatase treated section (left) or calf intestinal phosphatase-treated section (right).

ab84988 at 1/250 dilution staining RNA Polymerase II in serial sections of mouse teratoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue. Detection: DAB staining. Mock phosphatase treated section (left) or calf intestinal phosphatase-treated section (right).
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
